DHAKA: Bangladesh‘s Beximco Prescribed drugs Ltd will begin promoting a generic model of Merck & Co’s antiviral pill for Covid-19 following native regulatory approval, it mentioned on Tuesday.
The announcement marks the launch of the world’s first generic model of Merck and Ridgeback Biotherapeutics’ pill, molnupiravir, which has been touted as a possible game-changer within the struggle towards the coronavirus.
Molnupiravir acquired its first regulatory approval globally, within the UK final week. It’s nonetheless below overview in america and Europe.
Beximco will quickly start promoting generic molnupiravir, a less expensive model of Merck’s branded capsule, in Bangladesh, because it acquired emergency use authorisation for the remedy from the nation’s directorate basic of drug administration, it mentioned in an announcement. Exports would depend upon regulatory approvals globally, it added.
Merck didn’t instantly reply to a request for remark.
The US drugmaker has entered into licensing agreements with at the very least eight Indian drugmakers for molnupiravir, aiming to show the South Asian nation into a producing hub to produce low- and middle-income nations.
These embrace Dr Reddy’s Laboratories, Cipla , Solar Pharma, Torrent Prescribed drugs , Emcure Prescribed drugs and Hetero, amongst others.
Beximco mentioned it would not count on gross sales of the generic molnupiravir to considerably enhance revenues, given the presently low Covid-19 an infection fee in Bangladesh, which neighbours India.
Its London-listed shares have been up 6.2% at 107.25 pence by 0825 GMT.

Source link

Leave a Reply